Products & ReviewClinical Diagnostics

PreCursor-M+

Fujirebio81352Available: ,Western Europe,Asia,Eastern Europe,South Central America,Middle East,Africa,

Qualitative detection of promotor hypermethylation of 2 cervical cancer associated genes (FAM19A4 and hsa-miR124-2). Identify HPV positive women with high short-term progression to (pre)cancer.

Request Pricing
Fujirebio

Receive your quote directly from the manufacturer.

Ease of Use
After Sales Service
Value for Money
Be the first to leave a review

Sample types:

  • Bisulfite-converted DNA isolated from physician collected cervical specimens or self-collected vaginal specimens

Clinical performance - Long-term data:

  • Most evaluated and validated methylation assay to identify HPV positive women with progressing cervical disease in direct need for colposcopy or other follow-up procedures1,2
  • Demonstrating very high sensitivity for cervical cancer detection (95.0-100%) in HPV-positive cervical specimens2,3,4
  • Longitudinal data: The long-term risk for cancer with a negative PreCursor-M+ is lower than with a negative cytology result; for CIN3 the long-term risk is similar as cytology5,6

Flexible:

  • Suitable for various sample types, including self-samples and common Liquid Based Cytology media types
  • Compatible with standard DNA extraction methods

Reliable:

  • Build-in check for sample quality ensuring reliable results

Product Overview

Links